GHRP-6 vs Pentadeca Arginate (PDA)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

GHRP-6Pentadeca Arginate (PDA)
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
TimingOn empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.Administer on an empty stomach. Inject near site of injury for localized effect.
Cycle Duration8-16 week cycles.4-12 weeks depending on therapeutic target.
Evidence Levelmoderate_humananimal_plus_anecdotal
A

GHRP-6

Peptides

Mechanism

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates GH release through activation of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) on pituitary somatotrophs. It acts via dual sites — pituitary and hypothalamic — possibly involving regulatory factors beyond GHRH and somatostatin. GHRP-6 also stimulates ghrelin-mediated appetite signaling, increases cortisol and prolactin release, and has demonstrated cytoprotective properties including cardioprotection.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.

Cycle Duration

8-16 week cycles.

Side Effects

  • Intense hunger (primary distinguishing side effect)
  • Water retention
  • Cortisol elevation
  • Prolactin elevation
  • Tingling and numbness
  • Injection site pain

Contraindications

  • Active cancer
  • Obesity (significant appetite stimulation)
  • Cushing's syndrome
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)Sermorelin

Mechanism

Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.

Timing

Administer on an empty stomach. Inject near site of injury for localized effect.

Cycle Duration

4-12 weeks depending on therapeutic target.

Side Effects

  • Mild nausea (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuCJC-1295/Ipamorelin

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →